6 completed, 1 terminated, 1 withdrawn. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow BMS-986094: new trials by email Literature Review of BMS-986094 trials Research Report on BMS-986094
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C Daclatasvir, BMS-986094, Ribavirin - Hepatitis C Virus | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2013-03-01 | 2014-05-09 | |
| A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) BMS-986094/INX-08189, Placebo matching BMS-986094/INX-08189 - Healthy, Hepatitis C | Completed | Bristol-Myers Squibb | 113 | 2012-11-01 | 2014-08-15 | |
| Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a - Hepatitis C | Phase 2 | Terminated | Bristol-Myers Squibb | 210 | 2012-05-01 | 2015-11-04 |
| Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days - Healthy | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 32 | 2011-10-01 | 2012-06-22 |
| Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers INX-08189 50 mg, 240 mg verapamil HCL ER, 50 mg dose of INX-08189 and 240 mg verapamil HCL ER - Healthy | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 24 | 2011-10-01 | 2012-06-22 |
| Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD - Hepatitis C | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 50 | 2011-09-01 | 2016-06-27 |
| Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects INX-08189, Placebo matching with INX-08189, Ribavirin - HCV (Genotype 1) | Phase 1 | Completed | Bristol-Myers Squibb | 70 | 2010-10-01 | 2012-07-12 |
| A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects INX-08189, Placebo - Healthy | Phase 1 | Completed | Bristol-Myers Squibb | 42 | 2010-05-01 | 2012-06-22 |
Hepatitis C (5) · Hepatitis, Chronic (2)
United States (7) · Puerto Rico (3)